# Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban

> **NCT01826266** · PHASE1 · COMPLETED · sponsor: **Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.** · enrollment: 83 (actual)

## Conditions studied

- Anticoagulant Reversal
- Reversal of Edoxaban Induced Anticoagulation

## Interventions

- **DRUG:** PER977, Placebo

## Key facts

- **NCT ID:** NCT01826266
- **Lead sponsor:** Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2020-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01826266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01826266, "Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT01826266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*